What you missed at AAO 2024: Gildeuretinol acetate (ALK-001)
Nov 26, 2024 · Patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) treated with investigational oral therapy gildeuretinol (ALK-001) showed a statistically significant reduction in the GA lesion growth rate of 15.3% vs. placebo from 6 to 24 months (p=0.047). 1 In addition to the reduction in lesion growth, gildeuretinol also demonstrated a statistically significant ...
Modern Retina | Ophthalmology News, Events & Expert Insights
January 15th 2025. The retrospective SING IMT study included 35 patients (55 years or older) with late-stage age-related macular degeneration (AMD).
Curcuma-based nutritional supplements and reduced risk of AMD
Oct 25, 2024 · The results of a new retrospective cohort study suggest that use of curcuma-based nutritional supplements (CBNS) may be associated with the reduced risk of developing age-related macular degeneration (AMD) or progression to the later disease stages, 1 according to the first author Amer F. Alsoudi, MD, from the Department of Ophthalmology, Baylor College of Medicine, Houston.
More than 300 patients randomized in the SOL-1 Phase 3 trial for …
Dec 3, 2024 · More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). The trial is expected to close randomization in early December 2024.
US FDA issues Complete Response Letter for avacincaptad pegol ...
Nov 19, 2024 · Astellas Pharma Inc. announced the United States Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for avacincaptad pegol intravitreal solution (IZERVAY).
Phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis ...
Dec 11, 2024 · The phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis did not meet the primary endpoint of a statistically significant improvement in time to treatment failure versus placebo as measured by treatment failure rates at 24 weeks.
New data on PST-611 from PulseSight Therapeutics SAS shared at …
Nov 13, 2024 · PulseSight Therapeutics SAS presented new data on its lead program PST-611, a DNA plasmid expressing human transferrin, in dry age-related macular degeneration (AMD) and geographic atrophy (GA) at the European Association …
Retinopathy associated with hair dye - modernretina.com
Dec 8, 2024 · A recent French study reported that aromatic amines in hair dye are associated with development of retinopathy, 1 according to Nicolas Chirpaz, MD, first author, from the Ophthalmology Department, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France. Chirpaz and colleagues described the presence of multiple bilateral serous retinal detachments (SRDs) found in 3 women after they used ...
Beacon Therapeutics announces positive 3-month data from …
Dec 9, 2024 · Beacon Therapeutics presented 3-month interim safety and efficacy data from the Phase 2 DAWN trial of laru-zova (AGTC-501) for X-linked retinitis pigmentosa (XLRP) at the FLORetina ICOOR 2024 meeting in Florence, Italy.
Study: CRVO patients face higher heart attack risk
Dec 7, 2024 · A new Chinese study reported a strong connection between retinal vein occlusion (RVO) and myocardial infarction (MI), otherwise known as a heart attack.1 Study authors are led by Kai-Yang Chen, a medical student in the School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.